Scribe Therapeutics Inc. announced that it will receive $75 million in a round of funding on May 16, 2023. The transaction will include participation from new investor Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly. The company will issue convertible note and post completion will be converted into equity investment.

The company is eligible to receive more than $1.5 billion in the transaction.